Literature DB >> 10428934

Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.

S Palmer1, R W Shafer, T C Merigan.   

Abstract

We assessed the effects of hydroxyurea (HU) at a concentration of 50 microM on the in vitro activities of 2',3'-dideoxyinosine (ddI), 9-[2-(phosphonylmethoxy)ethyl]adenine (PMEA), and 9-[2-(phosphonylmethoxy)propyl]adenine (PMPA) against a wild-type human immunodeficiency virus (HIV) type 1 (HIV-1) laboratory isolate and a panel of five well-characterized drug-resistant HIV isolates. Fifty micromolar HU significantly increased the activities of ddI, PMEA, and PMPA against both the wild-type and the drug-resistant HIV-1 isolates. In fixed combinations, both ddI and PMEA were synergistic with HU against wild-type and drug-resistant viruses.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10428934      PMCID： PMC89412     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  37 in total

Review 1.  HIV inhibitors targeted at the reverse transcriptase.

Authors:  E De Clercq
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

Review 2.  An overview of the clinical experience with hydroxyurea.

Authors:  R C Donehower
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

3.  9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys.

Authors:  J Balzarini; L Naesens; J Slachmuylders; H Niphuis; I Rosenberg; A Holý; H Schellekens; E De Clercq
Journal:  AIDS       Date:  1991-01       Impact factor: 4.177

4.  Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine.

Authors:  M S Smith; E L Brian; E De Clercq; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Amplification of the genes for both components of ribonucleotide reductase in hydroxyurea resistant mammalian cells.

Authors:  R A Hurta; J A Wright
Journal:  Biochem Biophys Res Commun       Date:  1990-02-28       Impact factor: 3.575

6.  Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents.

Authors:  R Pauwels; J Balzarini; D Schols; M Baba; J Desmyter; I Rosenberg; A Holy; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

7.  Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.

Authors:  W Y Gao; A Cara; R C Gallo; F Lori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

Authors:  M D Miller; P D Lamy; M D Fuller; A S Mulato; N A Margot; T Cihlar; J M Cherrington
Journal:  Mol Pharmacol       Date:  1998-08       Impact factor: 4.436

9.  Relations between synthesis of deoxyribonucleotides and DNA replication in 3T6 fibroblasts.

Authors:  B Nicander; P Reichard
Journal:  J Biol Chem       Date:  1985-05-10       Impact factor: 5.157

Review 10.  Nucleoside analogs: similarities and differences.

Authors:  J P Sommadossi
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079
View more
  5 in total

1.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Authors:  Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

2.  Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.

Authors:  J Neyts; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 3.  Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Authors:  Julianna Lisziewicz; Andrea Foli; Mark Wainberg; Franco Lori
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Charles E Davis; Marvin S Reitz; Nhut M Le; Mark A Wainberg; James S Foulke; Lai-Xi Wang; Robert R Redfield
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

5.  VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

Authors:  Franco Lori; Davide De Forni; Elly Katabira; Denis Baev; Renato Maserati; Sandra A Calarota; Pedro Cahn; Marco Testori; Aza Rakhmanova; Michael R Stevens
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.